Lung cancer (Amsterdam, Netherlands) · 2026
Surgery after neoadjuvant immunochemotherapy versus immuno-chemoradiotherapy in patients with cN3 non-small cell lung cancer: A cohort study in two academic centers.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhai Wenyu, Liang Dachuan, Yu Xiangyang, Dai Shuqin, Guo Xiaotong, Zhou Yuheng, Yan Qihang, Li Liang, Yang Jie, Wong Wingshing, Gong Li, Duan Fangfang, Li Xiaodong, Wang Junye
Аннотация
BACKGROUND: Clinically N3 (cN3) stage non-small cell lung cancer (NSCLC) has historically been considered unresectable. While neoadjuvant immunochemotherapy demonstrates unprecedented pathological responses in earlier-stage disease, its role in enabling surgical resection versus definitive immuno-chemoradiotherapy for cN3 NSCLC remains undefined.
METHODS: This multicenter retrospective study (2017-2024) analyzed 196 patients with stage IIIB-IIIC (cT1-4 N3) NSCLC from two academic centers. Eighty-two patients received neoadjuvant immunochemotherapy followed by surgery (surgery group), while 114 underwent definitive immuno-chemoradiotherapy (radiotherapy group). Propensity score matching (PSM) balanced baseline characteristics. Primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS) and pathological complete response (pCR).
RESULTS: After PSM (74 per group), no overall PFS difference was observed (surgery: 32.2 months vs. radiotherapy: 21.3 months, P = 0.094). But surgery was associated with a significant OS benefit (median not reached vs 71.3 months, P = 0.012). Furthermore, only surgical patients achieving pCR (PFS: not reached vs. 21.3 months, P = 0.001; OS: not reached vs. 71.3 months, P = 0.019) or nodal clearance (ypN0) (PFS: not reached vs. 21.3 months, P = 0.010, OS: not reached vs. 71.3 months, P = 0.009) showed superior PFS and OS versus radiotherapy. Recurrence pattern differed between the two groups: Among locoregional failure patterns, all events in the surgery group were regional lymph node recurrences, whereas radiotherapy failures primarily involved primary site progression (59.3%), followed by regional nodal recurrence (39.7%).
CONCLUSION: Surgery after neoadjuvant immunochemotherapy demonstrated survival advantage over immuno-chemoradiotherapy in cN3 NSCLC. Significant survival benefits were confined to surgical patients attaining pCR or ypN0, highlighting the need for biomarker-driven patient selection.
METHODS: This multicenter retrospective study (2017-2024) analyzed 196 patients with stage IIIB-IIIC (cT1-4 N3) NSCLC from two academic centers. Eighty-two patients received neoadjuvant immunochemotherapy followed by surgery (surgery group), while 114 underwent definitive immuno-chemoradiotherapy (radiotherapy group). Propensity score matching (PSM) balanced baseline characteristics. Primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS) and pathological complete response (pCR).
RESULTS: After PSM (74 per group), no overall PFS difference was observed (surgery: 32.2 months vs. radiotherapy: 21.3 months, P = 0.094). But surgery was associated with a significant OS benefit (median not reached vs 71.3 months, P = 0.012). Furthermore, only surgical patients achieving pCR (PFS: not reached vs. 21.3 months, P = 0.001; OS: not reached vs. 71.3 months, P = 0.019) or nodal clearance (ypN0) (PFS: not reached vs. 21.3 months, P = 0.010, OS: not reached vs. 71.3 months, P = 0.009) showed superior PFS and OS versus radiotherapy. Recurrence pattern differed between the two groups: Among locoregional failure patterns, all events in the surgery group were regional lymph node recurrences, whereas radiotherapy failures primarily involved primary site progression (59.3%), followed by regional nodal recurrence (39.7%).
CONCLUSION: Surgery after neoadjuvant immunochemotherapy demonstrated survival advantage over immuno-chemoradiotherapy in cN3 NSCLC. Significant survival benefits were confined to surgical patients attaining pCR or ypN0, highlighting the need for biomarker-driven patient selection.